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total costs may be much greater when the high levels of
post-acute care are fully captured.
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OBJECTIVE: Only hip protectors, calcium and vitamin
D therapy and bisphosphonates have been shown to re-
duce hip fractures with the latter having the more robust
evidence. Three bisphosphonate are currently widely avail-
able but at differing costs, we compared the cost-effec-
tiveness of the two least expensive compounds (etidr-
onate & residronate). METHODS: We used a Markov
model to compare costs and health states of 1000 women
aged 75 years with a prevalent vertebral fracture, and
treated with either etidronate or residronate for 3 years
and then followed through until aged 100 years. We as-
sumed treatment was only effective for the 3 years. Drug
costs were taken from MIMs, fracture costs were taken
from published estimates and uprated to 1999 prices,
with hip fracture incurring a cost of £13,000 in the first
year and £7,000 in the second year. Hip fractures were
assumed to be reduced by 58% as evidenced in the most
recent trial and 33% for non hip and non vertebral frac-
tures for the residronate treated group. For etidronate
observational data suggests that it reduces hip fractures
by 34% and non hip and non vertebral fractures by
20%. We also assumed a loss of 0.32 QALYs in the year
of fracture. RESULTS: Residronate was revealed as the
dominant therapy for treating women of 75 years with a
previous vertebral fracture. Estimates of total cost sav-
ings per patient with a moderate vertebral deformity
were £10,627 and £10,857 for residronate and etidro-
nate respectively. Similarly, QALYs per patient gained
were 7.58 and 7.56 for residronate and etidronate, re-
spectively. Sensitivity analysis confirmed the robustness
of residronate’s dominancy. CONCLUSION: In the base-
line analysis both treatments are cost saving. Residronate
even seems to be cost saving when compared with etidr-
onate. Thus, residronate therapy dominates etidronate,
that is it saves more costs and produces more QALYs.
N Charges* LOS LTC%
Other
Care**%
Overall 57,807 $8,082 5.6 34.3% 29.4%
50–64 4,116 $9,396 5.4 10.4% 24.5%
65–74 9,850 $8,661 5.5 23.0% 29.3%
75–84 24,321 $8,128 5.9 35.1% 31.0%
85 19,521 $7,455 5.7 44.2% 28.9%
*Updated to 2000 dollars by Medical Care component of CPI.
**Acute hospital, other facility, home care.
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OBJECTIVE: To determine the average annual cost of
treating carpal tunnel syndrome (CTS) in a managed care
population. METHODS: All subjects contained within
PharMetric’s Integrated Outcomes database possessing a
diagnosis of carpal tunnel syndrome (ETG  0174 or
0175) during 1996–1999 were eligible for study inclu-
sion. Patients were required to have 12 months of data
following the first (index) CTS diagnosis present. Patients
less than 18 years of age and greater than 90 years of age
were excluded. Carpal tunnel syndrome specific and total
pharmacy charges were captured for the study period.
RESULTS: 82,176 patients met the inclusion criteria.
The mean age was 46.5 years (SE  0.047), and 70.6%
of the sample was female. 82% of patients with CTS did
not require surgery. General practitioners/internal medi-
cine account for 73.0% of CTS diagnoses in a given year.
Before diagnosis, the mean annual CTS specific charges
per patient was $86.14 (SE  2.47). After diagnosis, the
mean annual CTS specific charges per patient was $1186.11
(SE  6.51). Post diagnosis, inpatient charges accounted
for 40.6% of CTS-related expenses, while outpatient and
pharmacy charges accounted for 55.5% and 1.7% re-
spectively. Oral steroid use increased slightly from
16.8% to 18.7% after diagnosis of CTS, while NSAID
use increased from 36.3% to 51.2%. Outpatient steroid
injections doubled from 5.7% to 11.9% after a diagnosis
of CTS. Soft tissue disorders and osteoarthritis were the
two comorbidities that occurred most frequently with a
diagnosis of CTS with 22.8% and 12.7%, respectively.
CONCLUSION: Patients in this study, once diagnosed
with CTS, noticed significantly increased medical ex-
penses, particularly outpatient charges. NSAIDs use and
outpatient steroid injections were the preferred modali-
ties of treatment once a diagnosis of CTS was made.
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OBJECTIVE: To examine health status factors associ-
ated with utilization of different types of antidiabetic
medication in managed-care enrolled older adults, and in
turn, to study the association between antidiabetic medi-
